# treatment_phases

name:
Balance of supply (including switching formulation) where the full duration of treatment available under a particular treatment phase was not requested in the preceding prescription


name:
Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months)


name:
Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months) - in a patient of any weight being administered a subcutaneous form of this biological medicine


name:
Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply


name:
Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply


name:
Initial 1 (New patient), Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply


name:
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply


name:
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply


name:
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply


name:
Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply


name:
Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply


name:
Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply


name:
Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply


name:
Initial treatment - Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years)


name:
Initial treatment - Initial 2 (Change or re-commencement of treatment after a break of less than 5 years)


name:
Initial treatment - Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years)


name:
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)


name:
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)


name:
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)


name:
Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)


name:
Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months)


name:
Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months in a patient weighing at least 30 kg)


name:
Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months in a patient weighing less than 30 kg)


name:
Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months)


name:
Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years)


name:
Initial treatment - Initial 3 (recommencement of a new treatment cycle after a break of more than 12 months in a patient weighing less than 30 kg)


name:
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)


name:
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)


name:
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)


name:
Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months in a patient weighing at least 30 kg)


name:
Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)


name:
Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab)


name:
Initial treatment with the subcutaneous form where a concurrent PBS authority application for the intravenously (IV) administered formulation is being made


